Hologic, Inc. (0J5Q.L) LSE

Currency In USD

AD

Hologic, Inc.

Address

250 Campus Drive

Marlborough, MA 01752

United States of America (the)

Phone

508 263 2900

Sector

Healthcare

Industry

Medical - Equipment & Services

Employees

7063

First IPO Date

January 29, 2018

Key Executives

NameTitlePayYear Born
Stephen MacMillanChairman, Chief Executive Officer & President3.17M1964
Jennifer SchneidersPresident of Diagnostic Solutions1.11M1969
Karleen ObertonChief Financial Officer1.36M1971
Anne LiddyGeneral Counsel1.42M1976
Jan VerstrekenGroup President of International1.44M1969
Essex MitchellChief Operating Officer1.53M1980
Scott ChristensenSenior Vice President of Global Supply Chain & Regulatory Affairs0N/A
Diana De Walt SPHRSenior Vice President of Global Human Resources01955
Monica Aguirre BerthelotVice President & Chief of Staff0N/A
Benjamin CohnVice President & Corporate Controller0N/A
Michael J. WattsCorporate Vice President of Investor Relations0N/A
Paul MalenchiniChief Information Officer0N/A
Mark HorvathPresident of Breast & Skeletal Health Solutions01963
Mark IrvingVice President & Corporate Secretary0N/A
Brandon SchnittkerPresident of GYN Surgical Solutions01985
AD

Description

Hologic, Inc., founded in 1985 and headquartered in Marlborough, Massachusetts, is a global medical technology company. It focuses on developing, manufacturing, and marketing diagnostics, medical imaging, and surgical solutions, with a primary emphasis on advancing women's health through early detection and therapeutic interventions. Its operations are structured into four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health, catering to markets across the United States, Europe, Asia-Pacific, and other global territories. In its Diagnostics division, Hologic provides a range of products, including Aptima molecular assays for identifying infectious microorganisms, viral load tests for conditions such as HIV, Hepatitis C, and Hepatitis B, alongside Aptima and Panther Fusion SARS-CoV-2 assays. Other offerings in this segment include the ThinPrep System for cytology applications, the Rapid Fetal Fibronectin Test to evaluate preterm birth risk, and various diagnostic tests for Group B Streptococcus. The Breast Health segment delivers extensive solutions for breast imaging and analytics. These encompass 2D and 3D digital mammography systems, advanced reading workstations, minimally invasive biopsy guidance systems and devices, breast biopsy markers and localization tools, specimen radiology, ultrasound, connectivity solutions, and products for breast-conserving surgery. Within its GYN Surgical offerings, the company supplies the NovaSure Endometrial Ablation System for managing abnormal uterine bleeding, the MyoSure Hysteroscopic Tissue Removal System for excising fibroids, polyps, and other uterine pathologies, and the Fluent Fluid Management System to facilitate liquid distention during hysteroscopic diagnostic and operative procedures. Its Skeletal Health division offers the Horizon DXA, a dual-energy X-ray system, and the Fluoroscan Insight FD mini C-arm, used for minimally invasive orthopedic surgical interventions. The company markets its products through both its direct sales and service personnel, as well as independent distributors and sales representatives.

AD